Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-2264
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-26T06:45:35.781925Z
status: published
lens: g_space
sector: health
headline: Quantified enhancement volume based on MRI as a prognostic biomarker for early recurrence in hepatocellular carcinoma
dek: To investigate the association between MRI multi-phase enhancement volume and early recurrence in patients with hepatocellular carcinoma (HCC). This multicenter retrospective study included 532 HCC patients who underwent hepatectomy and were divided into an internal cohort (n=372) and an external cohort (n=160). We automatically measured multi-phase enhanced volume on MRI using artificial intelligence techniques, including arterial phase enhancement volume fraction (AP_EnVF), portal venous phase enhancement volu…
gain_title: An AI-measured arterial phase enhancement volume fraction on preoperative MRI was independently associated with early recurrence after liver cancer surgery, in both an internal and an external patient group.
problem_title: (none)
trace_subject: (none)
gain_reading: An AI-measured arterial phase enhancement volume fraction on preoperative MRI was independently associated with early recurrence after liver cancer surgery, in both an internal and an external patient group.
gain_evidence: The AP_EnVF quantified by MRI was independently associated with early recurrence after hepatectomy in patients with HCC. | We automatically measured multi-phase enhanced volume on MRI using artificial intelligence techniques
problem_reading: (none)
problem_evidence: (none)
quick_read: Researchers analysed 532 patients with hepatocellular carcinoma who had liver surgery, split into an internal group of 372 and an external group of 160. They used artificial intelligence to automatically measure how much of the tumour enhanced on MRI in the arterial, portal venous and delayed phases.

Of the three measures, only the arterial phase one tracked with early recurrence, which suggests it could help flag higher-risk patients before surgery. Because the work is retrospective, it shows an association rather than proof that using the measure improves patient outcomes.
limitation: 
tag: Evidence-backed gain
key_points: The study was multicenter and retrospective, covering 532 patients who underwent hepatectomy for hepatocellular carcinoma. | Each 15% decrease in preoperative AP_EnVF was linked to higher early recurrence risk, with a hazard ratio of 1.63 in the internal cohort. | In the external cohort, the same decrease in AP_EnVF was linked to a hazard ratio of 2.54. | Portal venous and delayed phase enhancement fractions showed no significant predictive value (both p > 0.05).
rundown: The team split patients into an internal cohort of 372 and an external cohort of 160, which let them test whether the finding held in a separate group. Independent predictors were identified with Lasso-Cox and multivariable Cox regression.

Three AI-derived measures were compared: arterial phase, portal venous phase and delayed phase enhancement volume fractions. Only the arterial phase fraction (AP_EnVF) was a significant predictor of early recurrence in both cohorts, with confidence intervals of 1.12 to 2.37 and 1.18 to 5.47 respectively.
sources:
- peer_reviewed | BMC Medical Imaging | https://doi.org/10.1186/s12880-026-02976-y | 2026-10-24
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

86e334041a3e7f5f8ddc3b154365032dbd9391b0e216bb7f98b53294c50a8c4a

previous

0000000000000000000000000000000000000000000000000000000000000000